Sensitization Strategies in Cancer Treatment

Message from the Guest Editor

Dear Colleagues,

Due to high mortality rates and increasing incidence, cancer research efforts should focus on delineating the molecular basis of tumor resistance to current therapies, which will aid in designing novel strategies or improving the existing ones. Induction of apoptosis is the favored mode of action of most anti-neoplastic chemotherapeutics to eradicate tumors. To avoid apoptosis, tumors assume various mechanisms. For instance, natural apoptosis inhibitors, such as anti-apoptotic Bcl-2 and Inhibitors of Apoptosis (IAP) family members employ different mechanisms to protect tumors against apoptosis induced by anti-cancer agents. Drug-resistance is additionally strengthened by the appearance of the multi-drug resistance (MDR) phenotype following initial chemotherapy administration.

This Special Issue will highlight the power of tumor sensitization to apoptosis, covering both basic and (pre)clinical aspects that advance our understanding and provide rational molecular basis for its utilization in clinical oncology.

Dr. Ali R. Jazirehi
Guest Editor
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.0 days after submission; acceptance to publication is undertaken in 4.0 days (median values for papers published in this journal in the second half of 2019).

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI